


Technology Advisory Committee B Interests Register

Topic: Cladribine for treating relapsing multiple sclerosis [ID6263]

Publication Date: 15 April 2025

| Name | Role with NICE | Type of interest | Description of interest | Interest declared | Comments |
|------------------|-----------------|---------------------------|--|--------------------------|--|
| Ruth Dobson | Clinical Expert | Non direct – financial | Her institution has received research funding from Merck for a project (2019 – present) and compensation for her time from Sandon (2023 – 2024) Other past funding to her institution has come from Celgene, Biogen, Janssen, Novartis and Roche She is currently a PI on a clinical trial sponsored by Roche (2021-present) for which her institution receives support. | 05/02/2025 | It was agreed that Ruth Dobson's declaration would not prevent her from providing expert advice to the committee. |
| Clair Winchester | Patient Expert | | The nominating organisation (MS Trust) takes part in technology advisory boards, information campaigns and other events on behalf of people with MS. Many of these are not funded or expensed. | 05/02/2025 13/11/2024 | It was agreed that Wallace Brownlee's declaration would not prevent her from providing expert advice to the committee. |



| Name | Role with NICE | Type of interest | Description of interest | Interest declared | Comments |
|------------------|------------------------------|--|---|----------------------|--|
| | | | The nominating organisation has received funds from several commercial organisations for delivery of health professional events and education. | | |
| Wallace Brownlee | Clinical Expert | Non-direct financial | He has accepted speaker honoraria for educational activities sponsored by Merck, and participated in an advisory board He has received honoraria for participation in educational activities and/or consulting from Biogen, Neuraxpharm, Novartis, Roche, Sanofi, Sandoz and Viatris | 13/11/2024 | It was agreed that Wallace Brownlee's declaration would not prevent him from providing expert advice to the committee. |
| Daniel Gallacher | TAC A committee Member | Non-financial professional interests | Daniel works part of Warwick Evidence who are the EAG for the topic being discussed | 21/10/2024 | It was agreed that Daniel's declaration would prevent him from participating in discussions on this appraisal. |